^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
vibostolimab/pembrolizumab (MK-7684A)
i
Other names: MK-7684A, MK-7684/MK-3475, MK7684A, MK 7684A, MK7684/MK3475, MK 7684/MK 3475
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Merck (MSD)
Drug class:
PD1 inhibitor, TIGIT inhibitor
Related drugs:
18d
KEYMAKER-U04 Substudy: A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04) (clinicaltrials.gov)
P1/2, N=390, Active, not recruiting, Merck Sharp & Dohme LLC | Completed --> Active, not recruiting | N=49 --> 390
Enrollment closed • Enrollment change
|
PD-L1 (Programmed death ligand 1)
|
Padcev (enfortumab vedotin-ejfv) • favezelimab/pembrolizumab (MK-4280A) • vibostolimab/pembrolizumab (MK-7684A)
2ms
KEYMAKER-U04 Substudy: A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04) (clinicaltrials.gov)
P1/2, N=49, Completed, Merck Sharp & Dohme LLC | N=37 --> 49
Enrollment change
|
PD-L1 (Programmed death ligand 1)
|
Padcev (enfortumab vedotin-ejfv) • favezelimab/pembrolizumab (MK-4280A) • vibostolimab/pembrolizumab (MK-7684A)
2ms
KEYMAKER-U04 Substudy: A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04) (clinicaltrials.gov)
P1/2, N=390, Completed, Merck Sharp & Dohme LLC | Recruiting --> Completed
Trial completion
|
PD-L1 (Programmed death ligand 1)
|
Padcev (enfortumab vedotin-ejfv) • favezelimab/pembrolizumab (MK-4280A) • vibostolimab/pembrolizumab (MK-7684A)
3ms
Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003) (clinicaltrials.gov)
P3, N=1264, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
Trial completion
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • PD-1 (Programmed cell death 1)
|
PD-L1 expression
|
Keytruda (pembrolizumab) • vibostolimab/pembrolizumab (MK-7684A)
3ms
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) (clinicaltrials.gov)
P1/2, N=1200, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Oct 2027 --> Jul 2028
Trial completion date
|
Keytruda (pembrolizumab) • Lynparza (olaparib) • carboplatin • docetaxel • Lenvima (lenvatinib) • enzalutamide • abiraterone acetate • etoposide IV • prednisone • dexamethasone • Welireg (belzutifan) • vibostolimab/pembrolizumab (MK-7684A)
3ms
KEYVIBE 007: Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007) (clinicaltrials.gov)
P3, N=739, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
Trial completion
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • vibostolimab/pembrolizumab (MK-7684A)
6ms
Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057) (clinicaltrials.gov)
P2, N=296, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
Trial completion
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • favezelimab/pembrolizumab (MK-4280A) • vibostolimab/pembrolizumab (MK-7684A)
7ms
A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010) (clinicaltrials.gov)
P3, N=1594, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
Trial completion
|
Keytruda (pembrolizumab) • vibostolimab/pembrolizumab (MK-7684A)
8ms
Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057) (clinicaltrials.gov)
P2, N=320, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Aug 2030 --> Oct 2025 | Trial primary completion date: Aug 2026 --> Oct 2025
Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • favezelimab/pembrolizumab (MK-4280A) • vibostolimab/pembrolizumab (MK-7684A)
9ms
A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010) (clinicaltrials.gov)
P3, N=1594, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Sep 2026 --> Sep 2025
Trial completion date
|
Keytruda (pembrolizumab) • vibostolimab/pembrolizumab (MK-7684A)
9ms
A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010) (clinicaltrials.gov)
P3, N=1594, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Aug 2025 --> Sep 2026
Trial completion date
|
Keytruda (pembrolizumab) • vibostolimab/pembrolizumab (MK-7684A)
9ms
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) (clinicaltrials.gov)
P2, N=613, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
Trial completion
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • docetaxel • 5-fluorouracil • Lenvima (lenvatinib) • capecitabine • albumin-bound paclitaxel • oxaliplatin • vibostolimab/pembrolizumab (MK-7684A)
Share via
